ARCA Biopharma Announces 1-For-12 Reverse Stock Split In Connection With The Proposed Merger With Oruka Therapeutics; To Begin Trading On A Post-reverse Stock Split Basis On The Nasdaq Global Market On September 3, 2024, And Under The New Symbol "ORKA"
ARCA Biopharma Announces 1-For-12 Reverse Stock Split In Connection With The Proposed Merger With Oruka Therapeutics; To Begin Trading On A Post-reverse Stock Split Basis On The Nasdaq Global Market On September 3, 2024, And Under The New Symbol "ORKA"
ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced that its Board of Directors (the "Board") has approved a reverse stock split of ARCA's common stock at a ratio of 1-for-12. ARCA's common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol "ORKA" following the anticipated closing of the merger with Oruka Therapeutics, Inc. (the "Merger"), with a new CUSIP number 687604108 and ISIN number US6876041087.
ARCA生物製藥公司（NASDAQ:ABIO）（"ARCA"）今天宣佈，其董事會（"董事會"）已批准將ARCA普通股進行1比12的股票合併。預計ARCA普通股將於2024年9月3日在納斯達克全球市場進行股票合併後開始交易，新名稱爲Oruka Therapeutics, Inc.，新標的爲"ORKA"，預計與Oruka Therapeutics, Inc.（"合併"）完成後，將採用新CUSIP號碼687604108和新ISIN號碼US6876041087。
The reverse stock split was approved by ARCA's stockholders at ARCA's special meeting of stockholders held on August 22, 2024 (the "Special Meeting"), to be effected in the Board's discretion of not less than 1-for-6 and not more than 1-for-12. The final reverse stock split ratio of 1-for-12 was approved by the Board on August 22, 2024.
ARCA的股東在2024年8月22日舉行的ARCA股東特別會議（"特別會議"）上批准了股票合併，由董事會自行決定股票合併比例不低於1比6，不高於1比12。1比12的最終股票合併比例於2024年8月22日董事會批准。
譯文內容由第三人軟體翻譯。
